Evaxion A/S (EVAX)

Market Cap	42.79M
Revenue (ttm)	7.65M
Net Income (ttm)	-5.42M
Shares Out	8.34M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,995
Open	4.75
Previous Close	4.70
Day's Range	4.60 - 5.28
52-Week Range	1.20 - 12.15
Beta	0.29
Analysts	Strong Buy
Price Target	12.33 (+140.35%)
Earnings Date	Nov 6, 2025

About EVAX

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vacci...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: EVAX
• Website: https://evaxion.ai

Financial Performance

In 2024, Evaxion's revenue was $3.34 million, an increase of 4480.82% compared to the previous year's $73,000. Losses were -$10.57 million, -52.24% less than in 2023.

Analyst Summary

According to 3 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price target is $12.33, which is an increase of 140.35% from the latest price.

Price Target

$12.33

(140.35% upside)

Analyst Consensus: Strong Buy